Penfluridol: An Efficacious Long-Acting Oral Antipsychotic Compound
Abstract
A six-month evaluation of penfluridol, a long-acting oral preparation, was conducted with 50 severely ill schizophrenic patients. After an initial three-month stabiization period, the patients were divided into two equal groups and a double-blind evaluation of penfluridol versus placebo was conducted. The results of this study indicate that weekly administration of penfluridol (one oral dose) provides relatively safe and adequate control of severely ill schizophrenic patients and displays efficacy similar to that of the shorter-acting antipsychotic agents. If these results are confirmed by other clinical investigators, this medication may prove to be of invaluable help in maintaining the schizophrenic patient in his community.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
